Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (415) 415
steroid 17-alpha-hydroxylase - antagonists & inhibitors (410) 410
male (386) 386
animals (303) 303
index medicus (279) 279
steroid 17-alpha-hydroxylase - metabolism (211) 211
prostatic neoplasms - drug therapy (143) 143
endocrinology & metabolism (140) 140
rats (139) 139
female (125) 125
enzyme inhibitors - pharmacology (119) 119
prostate cancer (115) 115
steroid 17-alpha-hydroxylase - genetics (110) 110
biochemistry & molecular biology (85) 85
oncology (84) 84
abiraterone acetate (79) 79
structure-activity relationship (74) 74
testis - enzymology (68) 68
chemistry, medicinal (66) 66
androgens (63) 63
cytochrome p-450 (63) 63
steroidogenesis (63) 63
testosterone (61) 61
enzyme inhibitors - chemistry (60) 60
microsomes - enzymology (60) 60
pharmacology & pharmacy (59) 59
abiraterone (58) 58
mice (58) 58
androgens - biosynthesis (56) 56
article (56) 56
cells, cultured (56) 56
androgen antagonists - therapeutic use (55) 55
cytochrome p-450 enzyme inhibitors (53) 53
prostatic neoplasms - pathology (53) 53
aged (52) 52
androstenes (52) 52
cyp17 (51) 51
expression (51) 51
kinetics (51) 51
middle aged (51) 51
prostatic neoplasms, castration-resistant - drug therapy (51) 51
androgen receptor (49) 49
cell line, tumor (49) 49
cancer (48) 48
rats, sprague-dawley (48) 48
enzyme inhibitors - chemical synthesis (47) 47
antineoplastic agents - therapeutic use (44) 44
receptors, androgen - metabolism (44) 44
aldehyde-lyases - antagonists & inhibitors (43) 43
enzyme inhibitors - therapeutic use (43) 43
ketoconazole (43) 43
enzymes (42) 42
testis - drug effects (42) 42
testosterone - blood (42) 42
imidazoles - pharmacology (41) 41
research (40) 40
androgens - metabolism (39) 39
antineoplastic agents - pharmacology (39) 39
androstenols - therapeutic use (38) 38
chemotherapy (38) 38
endocrine system (38) 38
physiological aspects (38) 38
aromatase - metabolism (37) 37
models, molecular (37) 37
prostatic neoplasms - enzymology (37) 37
testis - metabolism (37) 37
testosterone - biosynthesis (37) 37
treatment outcome (37) 37
antitumor-activity (36) 36
biosynthesis (36) 36
ketoconazole - pharmacology (36) 36
rna, messenger - metabolism (36) 36
steroid 17-alpha-hydroxylase (36) 36
urology & nephrology (36) 36
aromatase inhibitors (35) 35
orchiectomy (35) 35
progesterone - metabolism (35) 35
prostatic neoplasms - metabolism (35) 35
adult (34) 34
dose-response relationship, drug (34) 34
in-vitro (34) 34
prostate-cancer (34) 34
docetaxel (33) 33
androgen antagonists - pharmacology (32) 32
molecular structure (32) 32
steroids - biosynthesis (32) 32
aged, 80 and over (31) 31
drug design (31) 31
in vitro techniques (31) 31
androstadienes - therapeutic use (30) 30
cytochrome p-450 enzyme system - metabolism (30) 30
3-hydroxysteroid dehydrogenases - metabolism (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
care and treatment (29) 29
gene-expression (29) 29
abridged index medicus (28) 28
imidazoles - chemistry (28) 28
androstenols - pharmacology (27) 27
gene expression (27) 27
increased survival (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (575) 575
Japanese (11) 11
French (7) 7
German (3) 3
Russian (3) 3
Chinese (2) 2
Danish (1) 1
Italian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. New drug treatment possibilities in castration resistant prostate carcinoma
by Meisel, A and Stenner, F
Praxis, ISSN 1661-8157, 09/2012, Volume 101, Issue 18, p. 1143
Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Immunotherapy - methods | Androgen Receptor Antagonists - therapeutic use | Prognosis | Humans | Bone Neoplasms - secondary | Drug Resistance, Neoplasm | Male | Palliative Care | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Androgen Receptor Antagonists - adverse effects | Orchiectomy | Taxoids - therapeutic use | Lung Neoplasms - secondary | Antineoplastic Agents - adverse effects | Aged | Bone Neoplasms - drug therapy | Lung Neoplasms - diagnosis | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects
Journal Article
Details down arrow
2. Full Text Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
by Fizazi, Karim and Tran, NamPhuong and Fein, Luis and Matsubara, Nobuaki and Rodriguez-Antolin, Alfredo and Alekseev, Boris Y and Özgüroğlu, Mustafa and Ye, Dingwei and Feyerabend, Susan and Protheroe, Andrew and De Porre, Peter and Kheoh, Thian and Park, Youn C and Todd, Mary B and Chi, Kim N and LATITUDE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 352 - 360
The addition of abiraterone, a drug that blocks endogenous androgen synthesis, to standard androgen-deprivation therapy in patients with newly diagnosed,... 
ANDROGEN-DEPRIVATION THERAPY | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | CLINICAL-TRIALS | DOUBLE-BLIND | LEUPROLIDE ACETATE | DOCETAXEL | CHEMOTHERAPY | NEOADJUVANT | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Androgen Antagonists - therapeutic use | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Prednisone | Research | Prostate cancer | Medical research | Prostate-specific antigen | Clinical trials | Metastasis | Patients | Cancer therapies | Metastases | Androgens | Chemotherapy | Pain | Castration | Medical prognosis | Hypokalemia | Death | Prostate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
by James, Nicholas D and de Bono, Johann S and Spears, Melissa R and Clarke, Noel W and Mason, Malcolm D and Dearnaley, David P and Ritchie, Alastair W.S and Amos, Claire L and Gilson, Clare and Jones, Rob J and Matheson, David and Millman, Robin and Attard, Gerhardt and Chowdhury, Simon and Cross, William R and Gillessen, Silke and Parker, Christopher C and Russell, J. Martin and Berthold, Dominik R and Brawley, Chris and Adab, Fawzi and Aung, San and Birtle, Alison J and Bowen, Jo and Brock, Susannah and Chakraborti, Prabir and Ferguson, Catherine and Gale, Joanna and Gray, Emma and Hingorani, Mohan and Hoskin, Peter J and Lester, Jason F and Malik, Zafar I and McKinna, Fiona and McPhail, Neil and Money-Kyrle, Julian and O’Sullivan, Joe and Parikh, Omi and Protheroe, Andrew and Robinson, Angus and Srihari, Narayanan N and Thomas, Carys and Wagstaff, John and Wylie, James and Zarkar, Anjali and Parmar, Mahesh K.B and Sydes, Matthew R and STAMPEDE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
The addition of abiraterone and prednisolone to standard androgen-deprivation therapy as the first treatment for patients with locally advanced or metastatic... 
ZOLEDRONIC ACID | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PLUS PREDNISONE | CONTROL ARM | STAMPEDE TRIAL | OPEN-LABEL | MULTISTAGE | RANDOMIZED CONTROLLED-TRIAL | DOCETAXEL | MULTIARM | Prednisolone - adverse effects | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - radiotherapy | Prednisolone - administration & dosage | Prostatic Neoplasms - surgery | Humans | Middle Aged | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Prostatic Neoplasms - drug therapy | Androgen suppression therapy | Usage | Care and treatment | Prostate cancer | Prednisolone | Medical research | Prostate-specific antigen | Clinical trials | Endocrine therapy | Oncology | Metastasis | Radiation therapy | Cancer therapies | Metastases | Mens health | Androgens | Medical prognosis | Death | Prostate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase
by Stefanachi, Angela and Favia, Angelo D and Nicolotti, Orazio and Leonetti, Francesco and Pisani, Leonardo and Catto, Marco and Zimmer, Christina and Hartmann, Rolf W and Carotti, Angelo
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2011, Volume 54, Issue 6, pp. 1613 - 1625
The design, synthesis, and biological evaluation of a series of new aromatase (AR, CYP19) inhibitors bearing an imidazole ring linked to a 7-substituted... 
ALDOSTERONE SYNTHASE INHIBITORS | CYP19 AROMATASE | CHEMISTRY, MEDICINAL | LIGAND DOCKING | PROSTATE-CANCER | ESTROGEN BIOSYNTHESIS | P450 17 | RECEPTOR MODULATORS SERMS | HIGHLY POTENT | POSTMENOPAUSAL BREAST-CANCER | NONSTEROIDAL INHIBITORS | Cell Line | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Escherichia coli - enzymology | Aromatase Inhibitors - pharmacology | Humans | Aromatase Inhibitors - chemistry | Imidazoles - chemistry | Models, Molecular | Coumarins - chemistry | Microsomes - enzymology | Placenta - enzymology | Imidazoles - pharmacology | Structure-Activity Relationship | Coumarins - pharmacology | Pregnancy | Coumarins - chemical synthesis | Drug Design | Protein Binding | Female | Ligands | Imidazoles - chemical synthesis | In Vitro Techniques | Aromatase Inhibitors - chemical synthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Abiraterone and Increased Survival in Metastatic Prostate Cancer
by de Bono, Johann S and Logothetis, Christopher J and Molina, Arturo and Fizazi, Karim and North, Scott and Chu, Luis and Chi, Kim N and Jones, Robert J and Goodman, Oscar B and Saad, Fred and Staffurth, John N and Mainwaring, Paul and Harland, Stephen and Flaig, Thomas W and Hutson, Thomas E and Cheng, Tina and Patterson, Helen and Hainsworth, John D and Ryan, Charles J and Sternberg, Cora N and Ellard, Susan L and Fléchon, Aude and Saleh, Mansoor and Scholz, Mark and Efstathiou, Eleni and Zivi, Andrea and Bianchini, Diletta and Loriot, Yohann and Chieffo, Nicole and Kheoh, Thian and Haqq, Christopher M and Scher, Howard I and COU-AA-301 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 21, pp. 1995 - 2005
In this study, abiraterone acetate inhibited androgen synthesis and prolonged survival by 4 months among men with castration-resistant prostate cancer that had... 
ANDROGEN-DEPRIVATION THERAPY | HUMAN CYTOCHROME P450(17-ALPHA) | MEDICINE, GENERAL & INTERNAL | WORKING GROUP | PLUS PREDNISONE | STEROIDAL INHIBITORS | CYP17 | CASTRATION | ACETATE | I CLINICAL-TRIAL | HORMONAL-THERAPY | Androstenols - adverse effects | Prostatic Neoplasms - pathology | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Androstenes | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Androgens - biosynthesis | Male | Treatment Outcome | Fatigue - chemically induced | Disease Progression | Prostatic Neoplasms - mortality | Androstenols - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Prednisone - therapeutic use | Prostatic Neoplasms - drug therapy | Hypertension | Fees & charges | Biotechnology | Medical research | Laboratories | Prostate-specific antigen | Oncology | Biosynthesis | Prednisone | Cancer therapies | Survival | Patients | Metastases | Studies | Androgens | Chemotherapy | Pain | Castration | Hypokalemia | Acetic acid | Prostate cancer | Prostate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
by Charles J. Ryan and Matthew R. Smith and Lawrence Fong and Jonathan E. Rosenberg and Philip Kantoff and Florence Raynaud and Vanessa Martins and Gloria Lee and Thian Kheoh and Jennifer Kim and Arturo Molina and Eric J. Small
Journal of Clinical Oncology, ISSN 0732-183X, 03/2010, Volume 28, Issue 9, pp. 1481 - 1488
Purpose Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the enzyme catalyst for two essential steps in androgen biosynthesis.... 
MITOXANTRONE PLUS PREDNISONE | ANTIANDROGEN WITHDRAWAL | ONCOLOGY | GUIDELINES | GENES | MECHANISMS | DOCETAXEL | EXPRESSION | CARCINOMA | Androgen Antagonists - pharmacokinetics | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - surgery | Humans | Middle Aged | Androstenes | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Prostate-Specific Antigen - blood | Androstenols - therapeutic use | Orchiectomy | Dose-Response Relationship, Drug | Ketoconazole - therapeutic use | Androstenols - pharmacokinetics | Aged, 80 and over | Androgen Antagonists - therapeutic use | Prostatic Neoplasms - blood | Aged | Antineoplastic Agents - pharmacokinetics | Androgens - metabolism | Prostatic Neoplasms - drug therapy | Index Medicus | Guc7 | Guc13 | Original Reports | Faze
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: Clinical evidence for cross-resistance?
by Mezynski, J and Pezaro, C and Bianchini, D and Zivi, A and Sandhu, S and Thompson, E and Hunt, J and Sheridan, E and Baikady, B and Sarvadikar, A and Maier, G and Reid, A.H.M and Mulick Cassidy, A and Olmos, D and Attard, G and deBono, J
Annals of Oncology, ISSN 0923-7534, 11/2012, Volume 23, Issue 11, pp. 2943 - 2947
Abiraterone and docetaxel are both approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone pre-docetaxel is... 
Castration-resistant prostate cancer | Response rate | Abiraterone | Androgen receptor | Docetaxel | TRIALS | PLUS PREDNISONE | response rate | GUIDELINES | PHASE-II | castration-resistant prostate cancer | METASTATIC PROSTATE-CANCER | WORKING GROUP | abiraterone | androgen receptor | ONCOLOGY | docetaxel | RECOMMENDATIONS | ACETATE | ANTIGEN | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Humans | Middle Aged | Receptors, Androgen - metabolism | Androstenes | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Disease Progression | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Androstenols - therapeutic use | Taxoids - therapeutic use | Drug Interactions | Aged, 80 and over | Aged | Testosterone - blood | Prostatic Neoplasms - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
by Alison H.M. Reid and Gerhardt Attard and Daniel C. Danila and Nikhil Babu Oommen and David Olmos and Peter C. Fong and L. Rhoda Molife and Joanne Hunt and Christina Messiou and Christopher Parker and David Dearnaley and Joost F. Swennenhuis and Leon W.M.M. Terstappen and Gloria Lee and Thian Kheoh and Arturo Molina and Charles J. Ryan and Eric Small and Howard I. Scher and Johann S. de Bono
Journal of Clinical Oncology, ISSN 0732-183X, 03/2010, Volume 28, Issue 9, pp. 1489 - 1495
Purpose The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17... 
SURVIVAL | II CLINICAL-TRIALS | WORKING GROUP | CIRCULATING TUMOR-CELLS | ONCOLOGY | RECOMMENDATIONS | TESTOSTERONE | DRUG DEVELOPMENT | END-POINTS | ANDROGENS | EXPRESSION | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms - surgery | Humans | Middle Aged | Androstenes | Male | Antineoplastic Agents - therapeutic use | Prostate-Specific Antigen - blood | Androstenols - therapeutic use | Orchiectomy | Taxoids - therapeutic use | Aged, 80 and over | Androgen Antagonists - therapeutic use | Prostatic Neoplasms - blood | Aged | Prostatic Neoplasms - drug therapy | Original Reports | Guc5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants
by Mostaghel, Elahe A and Marck, Brett T and Plymate, Stephen R and Vessella, Robert L and Balk, Stephen and Matsumoto, Alvin M and Nelson, Peter S and Montgomery, R. Bruce
Clinical Cancer Research, ISSN 1078-0432, 09/2011, Volume 17, Issue 18, pp. 5913 - 5925
Purpose: Abiraterone is a potent inhibitor of the steroidogenic enzyme CYP17A1 and suppresses tumor growth in patients with castration-resistant prostate... 
ANTIANDROGEN | ONCOLOGY | STEROIDAL INHIBITORS | GROWTH | GENE-EXPRESSION | THERAPEUTIC IMPLICATIONS | CYTOCHROME P450(17-ALPHA) | ANTITUMOR-ACTIVITY | ACETATE | PROGRESSION | DEHYDROGENASE | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Humans | Male | Gene Expression Profiling | Androstenols - therapeutic use | Biosynthetic Pathways - genetics | Prostatic Neoplasms - genetics | Gene Expression Regulation, Neoplastic - drug effects | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Disease Models, Animal | Androgens - secretion | Alternative Splicing - genetics | Androstenols - pharmacology | Androstenes | Mice, SCID | Prostatic Neoplasms - mortality | Orchiectomy | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Receptors, Androgen - genetics | Cell Proliferation - drug effects | Mice | Androgens - metabolism | steroidogenesis | abiraterone | androgen receptor splice variant | castration resistant prostate cancer | CYP17A1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer
by Njar, Vincent C. O and Brodie, Angela M. H
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2015, Volume 58, Issue 5, pp. 2077 - 2087
In our effort to discover potent and specific inhibitors of 17a-hydroxylase/17,20-lyase (CYP17), the key enzyme which catalyzes the biosynthesis of androgens... 
BREAST-CANCER | CYP17 INHIBITORS | IN-VITRO | CHEMISTRY, MEDICINAL | POTENTIAL AGENTS | ANTIANDROGEN | ANDROGEN SYNTHESIS | CELL-GROWTH | AROMATASE INHIBITORS | ANTITUMOR EFFICACY | ABIRATERONE | Androgen Receptor Antagonists - pharmacokinetics | Prostatic Neoplasms - pathology | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Signal Transduction | Humans | Benzimidazoles - pharmacokinetics | Male | Clinical Trials as Topic | Molecular Targeted Therapy | Drug Discovery | Tissue Distribution | Receptors, Androgen - chemistry | Androstadienes - therapeutic use | Molecular Structure | Androstadienes - pharmacokinetics | Prostatic Neoplasms - drug therapy | Benzimidazoles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
by Li, Zhenfei and Bishop, Andrew C and Alyamani, Mohammad and Garcia, Jorge A and Dreicer, Robert and Bunch, Dustin and Liu, Jiayan and Upadhyay, Sunil K and Auchus, Richard J and Sharifi, Nima
Nature, ISSN 0028-0836, 07/2015, Volume 523, Issue 7560, pp. 347 - 351
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5... 
ANDROGEN RECEPTOR | 3-BETA-HYDROXYSTEROID DEHYDROGENASE | CYP17A1 INHIBITION | MECHANISM | TESTOSTERONE | RATIONALE | MULTIDISCIPLINARY SCIENCES | INCREASED SURVIVAL | CHEMOTHERAPY | EXPOSURE | ENZALUTAMIDE | Chromatin - metabolism | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Androgens - biosynthesis | Male | Androstenes - pharmacology | Androgen Receptor Antagonists - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Biotransformation | Cell Division | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | 3-Hydroxysteroid Dehydrogenases - metabolism | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms - pathology | Androstenes - therapeutic use | 5-alpha Reductase Inhibitors - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Phenylthiohydantoin - analogs & derivatives | Androgen Receptor Antagonists - metabolism | Xenograft Model Antitumor Assays | Androstenes - chemistry | Animals | Biosynthetic Pathways - drug effects | Survival Analysis | 5-alpha Reductase Inhibitors - pharmacology | Androstenes - metabolism | Prostatic Neoplasms - enzymology | Mice | Steroid 17-alpha-Hydroxylase - metabolism | 5-alpha Reductase Inhibitors - metabolism | Androgens - metabolism | Enzymes | Testosterone | Androgens | Metabolites | Ligands | Gene expression | Prostate cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
by Logothetis, Christopher J, Prof and Basch, Ethan, MD and Molina, Arturo, MD and Fizazi, Karim, Prof and North, Scott A, MD and Chi, Kim N, MD and Jones, Robert J, MD and Goodman, Oscar B, MD and Mainwaring, Paul N, MD and Sternberg, Cora N, MD and Efstathiou, Eleni, MD and Gagnon, Dennis D, MA and Rothman, Margaret, PhD and Hao, Yanni, PhD and Liu, Cameron S, PhD and Kheoh, Thian S, PhD and Haqq, Christopher M, MD and Scher, Howard I, Prof and de Bono, Johann S, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1210 - 1217
Summary Background Bone metastases are a major cause of morbidity in metastatic castration-resistant prostate cancer. Abiraterone acetate potently disrupts... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | THERAPY | ONCOLOGY | MEN | DISEASE | CLINICAL IMPORTANCE | BONE | OUTCOMES | DOCETAXEL | CHEMOTHERAPY | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Glucocorticoids - administration & dosage | Humans | Middle Aged | Pain Management | Bone Neoplasms - secondary | Male | Palliative Care | Abiraterone Acetate | Aged, 80 and over | Adult | Drug Therapy, Combination | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Prednisone - administration & dosage | Double-Blind Method | Fractures, Spontaneous - etiology | Spinal Cord Compression - etiology | Bone Neoplasms - complications | Androstadienes - administration & dosage | Fractures, Spontaneous - prevention & control | Aged | Androgen Antagonists - administration & dosage | Pain Measurement | Spinal Cord Compression - prevention & control | Care and treatment | Corticosteroids | Oncology, Experimental | Prednisone | Metastasis | Research | Cancer patients | Chemotherapy | Pain | Comparative analysis | Prostate cancer | Steroids | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights